Westminster-based ARCA Biopharma Inc. (NASDAQ: ABIO) announced the completion of its merger with Oruka Therapeutics Inc. The merger follows ARCA’s successful receipt of stockholder approval for all related proposals at a special meeting on Aug. 22, 2024. The combined company will operate as “Oruka Therapeutics Inc.”, with its common stock to be traded on Nasdaq…
Annual Membership Required
You must be a Annual member to access this content.
Already a member? Log in here